camp elisa kit  (Elabscience Biotechnology)

Journal: Bioactive Materials

Article Title: Dynamic feedback BacGuard anchors microbial metabolism to host symbiosis in real-time ulcerative colitis therapy

doi: 10.1016/j.bioactmat.2026.05.060

Figure Lengend Snippet: BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration of IL-22 in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.

Article Snippet: For the detection of IL-22 and LPS concentrations, the Mouse IL-22 Precoated ELISA Kit (DAKEWE, China) and Mouse LPS ELISA Kit (JONLNBIO, China) were employed correspondingly.

Techniques: Immunofluorescence, Concentration Assay, Staining, Immunohistochemistry

Journal: Bioactive Materials

Article Title: Screening of a quinonoid compounds library identifies decylubiquinone as an antioxidant and anti-apoptotic agent against glucocorticoid-induced osteoporosis via CD39/CD73/adenosine axis

doi: 10.1016/j.bioactmat.2026.03.062

Figure Lengend Snippet: Roles of A 2b R in ADO-mediated activation of the cAMP/PKA/CREB pathway in primary BMSCs. ( A ) Principal component analysis (PCA) of RNA-seq data from primary BMSCs treated with Dex or Dex + ADO. ( B ) The volcano plot presented the differentially expressed genes (DEGs) as determined by RNA-Seq in primary BMSCs treated with Dex or Dex + ADO. ( C ) Gene Ontology (GO) enrichment analysis in the biological process category for DEGs as determined by RNA-Seq in primary BMSCs treated with Dex, or Dex + ADO. ( D ) The molecular docking of ADO with mus musculus A 1 R, A 2a R, A 2b R, and A 3 R proteins. ADO is displayed in Cyan. The surrounding residues in the binding pocket are shown in green (forming a non-hydrogen bond with ADO) or magenta (forming a hydrogen bond with ADO). The hydrogen bond is labeled as yellow dashed lines. The backbone of the receptor is depicted as gray. ( E ) RT-qPCR analysis of the mRNA levels of Adora1 , Adora2a , Adora2b , and Adora3 in primary BMSCs treated with vehicle, Dex, or Dex + ADO. ( F ) RT-qPCR analysis for the expression of Runx2 in primary BMSCs of different groups. (G) Gene Set Enrichment Analysis (GSEA) plot showing the differentially expressed pathway (cAMP) between the Dex group and the Dex + ADO group as indicated by Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. ( H ) Western blot validation for the knockdown deficiency of A 2b R after transfection with si Adora2b . ( I ) ELISA analysis for the relative intracellular cAMP levels in BMSCs of different groups. ( J ) Western blot and quantification for the expression of PKA, p-PKA, CREB, and p-CREB in primary BMSCs. ( K ) Representative images and quantitative analysis of Alizarin Red S staining for mineralization deposit in primary BMSCs of different groups under osteogenic conditions. n = 4 independent repeats by using different biological samples in each group for in vitro experiments. Data were means ± s.e.m. ns p > 0.05, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 by one-way ANOVA. Scale bar: 200 μm (K).

Article Snippet: The intracellular cAMP level was examined by using a cAMP ELISA Kit (E-EL-0056, Elabscience, Wuhan, China) according to the manufacturer's instructions.

Techniques: Activation Assay, RNA Sequencing, Binding Assay, Labeling, Quantitative RT-PCR, Expressing, Western Blot, Biomarker Discovery, Knockdown, Transfection, Enzyme-linked Immunosorbent Assay, Staining, In Vitro

Journal: Materials Futures

Article Title: A clinically defined and xeno-free hydrogel system for regenerative medicine

doi: 10.1088/2752-5724/ae4e4d

Figure Lengend Snippet: Substrate characterisation in 2D and 3D cell culture—biological responses and physical properties with different compositions. (a) hPSC confluence in 2D growth factor-reduced Matrigel (Geltrex), laminin 521, fibrin-laminin hydrogel, and fibrin gel after 4 d; scale bar = 100 μ m. (b) hPSCs cultured in 3D hydrogels. Top panel: fibrin (5 mg ml −1 ) gel. Bottom panel: Alphagel containing structures resembling pluripotent spheroids; scale bar = 200 μ m. Scanning electron microscopy of (c) fibrin gel and (d) Alphagel; scale bar = 1 μ m, magnification 20 K X, iProbe = 13 pA, 2.00 kV, Working Distancee = 4.4 mm for both images. (e) Young’s moduli in hydrogels with varying fibrin and laminin concentrations. One-way ANOVA; ** = p < 0.01, *** = p < 0.001, and **** = p < 0.0001. (f) Cell viability of hPSCs cultured in Alphagel, fibrin-only hydrogels, and 2D standard substrates. Mean ± sandard error of the mean displayed. t -test; * = p < 0.05. (g) ELISA of laminin 521 in culture media used with acellular Alphagel and (h) the calculated amount of fibrin-bound laminin.

Article Snippet: Apolipoprotein B (APOB) secretion in the supernatant was quantified using the human APOB ELISA quantification kit (Mabtech, no. 3715-1H-6) according to the product literature.

Techniques: Cell Culture, Electron Microscopy, Enzyme-linked Immunosorbent Assay

Journal: Materials Futures

Article Title: A clinically defined and xeno-free hydrogel system for regenerative medicine

doi: 10.1088/2752-5724/ae4e4d

Figure Lengend Snippet: Characterisation of iHeps derived in Alphagel, fibrin-only hydrogels, and Matrigel. (a) Key hepatocyte markers in Alphagel-derived iHeps. ALB = albumin, HNF = hepatocyte nuclear factor, CYP2A6 = Cytochrome P450 2A6, CD147 = cluster of differentiation protein 147, and E-CAD = E-cadherin. Scale bar = 25 μ m. (b) Key hepatocyte markers by gene expression (qPCR): CCAAT/enhancer-binding protein alpha (CEBPA), T-box transcription factor 3= TBX3, alpha-fetoprotein = AFP. (c) Albumin secretion (ELISA) and (d) CYP3A4 activity (P450-Glo TM ) in PHHs versus iHeps cultured in various gels (day 22). HCM = Hepatocyte Culture Media (Lonza). (e) LDL uptake (red) in Alphagel-derived iHeps versus hPSCs. Scale bar = 100 μ m. (f) CDFDA secretion (green) in Alphagel-derived iHeps versus hPSCs. Top panel scale bar = 20 μ m; bottom panel scale bar = 50 μ m. One-way ANOVA was used; * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** = p < 0.0001.

Article Snippet: Apolipoprotein B (APOB) secretion in the supernatant was quantified using the human APOB ELISA quantification kit (Mabtech, no. 3715-1H-6) according to the product literature.

Techniques: Derivative Assay, Gene Expression, Binding Assay, Enzyme-linked Immunosorbent Assay, Activity Assay, Cell Culture

Journal: Materials Futures

Article Title: A clinically defined and xeno-free hydrogel system for regenerative medicine

doi: 10.1088/2752-5724/ae4e4d

Figure Lengend Snippet: Characterisation of iHeps cultured in Hepatogel and its effect on cell retention after intra-hepatic cell transplantation. (a) Differentially expressed genes in iHeps: Hepatologel, Alphagel, Matrigel, and adult PHHs. (b) A heat map summarising the differential gene expression of a hepatic 24-gene panel across replicates of Matrigel, Alphagel, and Hepatogel (normalised to hPSC). (c) Albumin ELISA of culture media and (d) luciferin-based measure of CYP3A4 activity: 2 d after completion of iHep differentiation and 2 d after plating PHHs. One-way ANOVA; * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** = p < 0.0001. (e) Mouse livers 3 d after intra-hepatic injection with H-iHeps in Hepatogel and 0.9% saline. Red box = area magnified. * = site of injection, dotted white lines demarcate engrafted cell mass. Scale bar = 1 mm. (f) Human albumin (stained red) in engrafted iHeps 3 d after intra-hepatic injection. Scale bar = 100 μ m. (g) H-iHeps identified by albumin staining on liver histology 3 d after intra-hepatic injection. (h) ELISA of mouse serum for human albumin after injection with H-iHeps in Hepatogel and 0.9% saline over time. Day 0 = serum levels before injection. T -test; *** = p < 0.001 and **** = p < 0.0001.

Article Snippet: Apolipoprotein B (APOB) secretion in the supernatant was quantified using the human APOB ELISA quantification kit (Mabtech, no. 3715-1H-6) according to the product literature.

Techniques: Cell Culture, Transplantation Assay, Gene Expression, Enzyme-linked Immunosorbent Assay, Activity Assay, Injection, Saline, Staining

Journal: Bioactive Materials

Article Title: Screening of a quinonoid compounds library identifies decylubiquinone as an antioxidant and anti-apoptotic agent against glucocorticoid-induced osteoporosis via CD39/CD73/adenosine axis

doi: 10.1016/j.bioactmat.2026.03.062

Figure Lengend Snippet: Screening of the quinonoid compounds for the treatment of GIOP. (A) Flowchart depicting the screening process of the quinonoid compounds library. The schematic diagram was created by using BioRender.com. (B) Volcano diagram showing the effects of the 153 quinonoid compounds on Runx2 expression in BMSCs. Red and blue dots indicate the specific compounds that up- and down-regulate Runx2 expression in BMSCs, respectively. (C) Heat map showing the effect of the compounds on ALP activity in primary BMSCs. Color from blue to red indicates the ALP activity in primary BMSCs from low to high. (D) Measurement of intracellular ROS level in primary BMSCs treated with three potential compounds by using the fluorescent dye DCFDA. (E) Chemical structure of DUB, the final candidate among the screened drugs. (F) MTT assay for the proliferation of BMSCs treated with different doses of DUB for 2 and 10 days, under osteogenic induction conditions with or without 10 μM Dex. (G) Representative images and quantitative analysis of mineralized nodule formation via Alizarin Red S (ARS) staining in primary BMSCs treated with DUB at a series of concentrations, under osteogenic induction conditions with or without 10 μM Dex. (H) Western blot and quantification for the expression of osteogenesis-related proteins in primary BMSCs under different treatments. (I) Oil Red O staining and quantifications for lipid droplets in primary BMSCs of different groups. n = 4 independent repeats by using different biological samples in each group for in vitro experiments. Data were means ± s.e.m. ∗∗∗ p < 0.001 by one-way ANOVA. Scale bars: 200 μm (G), and 50 μm (I).

Article Snippet: The intracellular cAMP level was examined by using a cAMP ELISA Kit (E-EL-0056, Elabscience, Wuhan, China) according to the manufacturer's instructions.

Techniques: Expressing, Activity Assay, MTT Assay, Staining, Western Blot, In Vitro

Journal: Bioactive Materials

Article Title: Screening of a quinonoid compounds library identifies decylubiquinone as an antioxidant and anti-apoptotic agent against glucocorticoid-induced osteoporosis via CD39/CD73/adenosine axis

doi: 10.1016/j.bioactmat.2026.03.062

Figure Lengend Snippet: Roles of A 2b R in ADO-mediated activation of the cAMP/PKA/CREB pathway in primary BMSCs. ( A ) Principal component analysis (PCA) of RNA-seq data from primary BMSCs treated with Dex or Dex + ADO. ( B ) The volcano plot presented the differentially expressed genes (DEGs) as determined by RNA-Seq in primary BMSCs treated with Dex or Dex + ADO. ( C ) Gene Ontology (GO) enrichment analysis in the biological process category for DEGs as determined by RNA-Seq in primary BMSCs treated with Dex, or Dex + ADO. ( D ) The molecular docking of ADO with mus musculus A 1 R, A 2a R, A 2b R, and A 3 R proteins. ADO is displayed in Cyan. The surrounding residues in the binding pocket are shown in green (forming a non-hydrogen bond with ADO) or magenta (forming a hydrogen bond with ADO). The hydrogen bond is labeled as yellow dashed lines. The backbone of the receptor is depicted as gray. ( E ) RT-qPCR analysis of the mRNA levels of Adora1 , Adora2a , Adora2b , and Adora3 in primary BMSCs treated with vehicle, Dex, or Dex + ADO. ( F ) RT-qPCR analysis for the expression of Runx2 in primary BMSCs of different groups. (G) Gene Set Enrichment Analysis (GSEA) plot showing the differentially expressed pathway (cAMP) between the Dex group and the Dex + ADO group as indicated by Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. ( H ) Western blot validation for the knockdown deficiency of A 2b R after transfection with si Adora2b . ( I ) ELISA analysis for the relative intracellular cAMP levels in BMSCs of different groups. ( J ) Western blot and quantification for the expression of PKA, p-PKA, CREB, and p-CREB in primary BMSCs. ( K ) Representative images and quantitative analysis of Alizarin Red S staining for mineralization deposit in primary BMSCs of different groups under osteogenic conditions. n = 4 independent repeats by using different biological samples in each group for in vitro experiments. Data were means ± s.e.m. ns p > 0.05, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 by one-way ANOVA. Scale bar: 200 μm (K).

Article Snippet: The intracellular cAMP level was examined by using a cAMP ELISA Kit (E-EL-0056, Elabscience, Wuhan, China) according to the manufacturer's instructions.

Techniques: Activation Assay, RNA Sequencing, Binding Assay, Labeling, Quantitative RT-PCR, Expressing, Western Blot, Biomarker Discovery, Knockdown, Transfection, Enzyme-linked Immunosorbent Assay, Staining, In Vitro